BHVN Stock Overview
Focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biohaven Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$46.83 |
| 52 Week High | US$62.21 |
| 52 Week Low | US$26.80 |
| Beta | 4.12 |
| 11 Month Change | -8.78% |
| 3 Month Change | 17.19% |
| 1 Year Change | 54.71% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 541.51% |
Recent News & Updates
Biohaven: A Complicated Tale
Oct 11Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Recent updates
Biohaven: A Complicated Tale
Oct 11Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09Shareholder Returns
| BHVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | -6.5% | -1.0% |
| 1Y | 54.7% | 14.6% | 30.3% |
Return vs Industry: BHVN exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: BHVN exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| BHVN volatility | |
|---|---|
| BHVN Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BHVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BHVN's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 239 | Vlad Coric | www.biohaven.com |
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company’s pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson’s disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy.
Biohaven Ltd. Fundamentals Summary
| BHVN fundamental statistics | |
|---|---|
| Market cap | US$4.68b |
| Earnings (TTM) | -US$804.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.9x
P/E RatioIs BHVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHVN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$804.34m |
| Earnings | -US$804.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.95 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BHVN perform over the long term?
See historical performance and comparison